Liquid Biopsy to Detect Ovarian Cancer on the Horizon Available to Purchase

Abstract: Researchers have successfully developed a liquid biopsy ovarian cancer assay. Known as DELPHI-protein, the assay uses AI to cross reference the presence of cell-free DNA fragmentomes and biomarkers in patients’ blood. The test generates results that have more than twice the positive predictive value as currently available ovarian cancer tests and produces almost no false positive results.